Gilead Sciences is laying off 36 people as part of a rethink that saw the Big Pharma scrap plans to expand a biologics facility in California. At one point, the company had been planning to expand ...

Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.

Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health insurers to cover preventive care services including those for reducing HIV risk and ...

The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding for HIV prevention efforts.

AHF: Gilead’s Greed Kills Promise of Lenacapavir for HIV PreventionLUBLIN, Poland-- (BUSINESS WIRE)--Join AIDS Healthcare Foundation (AHF) Poland for a Menstrual Health Day commemorative event ...

Kim Canady was only nine years old in 1996 when she faced the unimaginable loss of losing both her parents in the same year. At the time, she didn’t know her parents suffered HIV-related complications ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 11 most profitable NASDAQ stocks to buy now. On June 11, RBC Capital increased its price target for Gilead Sciences to $95 from $92, while ...

Gilead Sciences partners with Kymera Therapeutics in a $750 million deal to develop molecular glue degraders for breast cancer treatment.